About Star ScientificStar Scientific is a technology-oriented company with a mission to reduce the harm associated with tobacco at every level. It is engaged in the development of dissolvable smokeless tobacco products that deliver fewer carcinogenic toxins, principally through the utilization of the innovative StarCured® tobacco curing technology. Its subsidiary, Rock Creek Pharmaceuticals, Inc., is involved in the development of nutraceuticals as well as products to address neurological and mood disorders. Rock Creek Pharmaceuticals has scientific and research offices in Gloucester, MA, and a regulatory office in Washington, DC. Star Scientific has a Corporate and Sales Office in Glen Allen, VA, an Executive, Scientific & Regulatory Affairs office in Bethesda, MD, and a manufacturing facility in Chase City, VA. Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50237280&lang=en
Rock Creek Pharmaceuticals, Inc., a wholly owned subsidiary of Star Scientific, Inc. (NASDAQ: CIGX), announced that Anatabloc ® Unflavored is available as an option on the shopping cart on the Anatabloc ® website at https://store.anatabloc.com/products as of today. Anatabloc ® Unflavored is a revised formulation containing the same active dietary ingredients in the same dose as our original Anatabloc ® product. A significant number of individuals using Anatabloc ® communicated to us their interest in an Anatabloc ® product without mint flavoring; others expressed an interest in a product that does not contain artificial sugar substitutes. Anatabloc ® Unflavored is a formulation that can be used by any current or new users of our Anatabloc ® product who wish to avoid sweeteners and flavors. The new formulation is the same as the original with respect to the other ingredients and can be used in the same manner.
Anatabloc(R) Unflavored (Photo: Business Wire)As of today, the Anatabloc ® Unflavored image appears on the main landing page for the Anatabloc ® website. Visitors to the website will be able to purchase Anatabloc ® Unflavored at a single, one-time purchase price of $99.99 or as part of our Advantage Club renewal program, at $79.99. Each bottle of Anatabloc ® Unflavored will contain 200 tablets. Curtis Wright, IV, MD/MPH, Senior Vice President and Medical Director of Rock Creek Pharmaceuticals said, “When we received the first request for an alternative formulation, there was never any doubt that we would try to fulfill it, since we anticipated that various consumers would want to have the benefit of using Anatabloc ® without artificial flavors or sweeteners. We are very pleased that our production team was able to develop a formulation free of artificial flavors and sweeteners for those customers who either do not care for the mint flavoring or prefer not to use artificial sweeteners for a variety of personal reasons. Our goal in formulating Anatabloc ® is to promote health and optimum nutrition, and removing barriers to use for any customer is always a good thing to do. Most people prefer the original formulation, but now Anatabloc ® users have another choice.” Jonnie R. Williams, CEO of Rock Creek’s parent company, Star Scientific, Inc., stated, “The brand extension of Anatabloc ® Unflavored tablets at this time underscores our commitment to be responsive to consumer demands as well as drive consumer acceptance.” Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical and low-TSNA tobacco products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, including with respect to our nutraceutical and low-TSNA tobacco products, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2011. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.